Who are NVP+AZT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): EFV, Tenofovir/Emtricitabine, AZT, Tenofovir (TDF), Twice-daily ABC+3TC, LPV/r + TDF/FTC or TDF/3TC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nvp-azt.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

NVP+AZT — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NVP+AZT (NVP+AZT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NNRTI + NRTI). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy (NNRTI + NRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

NVP+AZT (NVP+AZT) — Johns Hopkins Bloomberg School of Public Health. NVP+AZT is a combination antiretroviral therapy that inhibits HIV reverse transcriptase through two nucleoside reverse transcriptase inhibitors (NRTIs), preventing viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
NVP+AZT TARGET	NVP+AZT	Johns Hopkins Bloomberg School of Public Health	phase 3	Antiretroviral combination therapy (NNRTI + NRTI)	HIV reverse transcriptase
EFV	EFV	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV reverse transcriptase
Tenofovir/Emtricitabine	Tenofovir/Emtricitabine	Bristol-Myers Squibb	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV reverse transcriptase
AZT	AZT	Johns Hopkins Bloomberg School of Public Health	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
Tenofovir (TDF)	Tenofovir (TDF)	French National Agency for Research on AIDS and Viral Hepatitis	marketed	Nucleotide reverse transcriptase inhibitor (NtRTI)	HIV reverse transcriptase; Hepatitis B polymerase
Twice-daily ABC+3TC	Twice-daily ABC+3TC	Medical Research Council	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
LPV/r + TDF/FTC or TDF/3TC	LPV/r + TDF/FTC or TDF/3TC	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NNRTI + NRTI) class)

Johns Hopkins Bloomberg School of Public Health · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NVP+AZT — Competitive Intelligence Brief. https://druglandscape.com/ci/nvp-azt. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab